MedTrace Logo

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

NCT04778410 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2025-03-20

Study results available
· View outcomes & findings →

Summary

The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).

Conditions

  • Myeloid Malignancies

Interventions

DRUG

Magrolimab

Administered intravenously

DRUG

Azacitidine

Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle

DRUG

Venetoclax

Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle

DRUG

Mitoxantrone

Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3

DRUG

Etoposide

Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3

DRUG

Cytarabine

Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3

DRUG

CC-486

Administered orally, 300 mg on Days 1-14 during each cycle

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-28
Primary Completion
2024-03-04
Completion
2024-03-04
FDA Drug
Yes

Countries

  • United States
  • Australia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04778410 on ClinicalTrials.gov